Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: Evidence from the Framingham Heart Study

Authors

Ping An, Washington University School of Medicine in St. Louis
Mary Feitosa, Washington University School of Medicine in St. LouisFollow
Shamika Ketkar, Washington University School of Medicine in St. Louis
Avril Adelman, Washington University School of Medicine in St. Louis
Shiow Lin, Washington University School of Medicine in St. Louis
Ingrid Borecki, Washington University School of Medicine in St. LouisFollow
Michael Province, Washington University School of Medicine in St. Louis

Journal

BMC Proceedings

Publication Date

2009

Volume

3

Issue

Suppl 7

Inclusive Pages

S71

Document Type

Open Access Publication

Rights and Permissions

BMC Proceedings 2009, 3(Suppl 7):S71 http://www.biomedcentral.com/1753-6561/3/S7/S71 © 2009 An et al; licensee BioMed Central Ltd.

Recommended Citation

An, Ping; Feitosa, Mary; Ketkar, Shamika; Adelman, Avril; Lin, Shiow; Borecki, Ingrid; and Province, Michael, "Epistatic interactions of CDKN2B-TCF7L2 for risk of type 2 diabetes and of CDKN2B-JAZF1 for triglyceride/high-density lipoprotein ratio longitudinal change: Evidence from the Framingham Heart Study." BMC Proceedings. 3, Suppl 7. S71. (2009).
https://digitalcommons.wustl.edu/open_access_pubs/285